Who Paid My Doc
Unituxin
Drug Neuroblastoma
NDC 66302-014-01
General payments
$4,951
Research payments
$143,970
Through program year 2025, $4,951 in general payments and $143,970 in research payments were reported against Unituxin (Neuroblastoma).
No combined total These are different kinds of money, reported under different rules. A meal and a clinical trial grant do not add up to anything meaningful, so this site does not add them.
By program year
4 rows| Year | Kind | Amount | Payments |
|---|---|---|---|
| 2025 | General | $1,482 | 26 |
| 2025 | Research | $128,114 | 5 |
| 2024 | General | $3,470 | 46 |
| 2024 | Research | $15,856 | 3 |
Breakdown
The top 5 of 20 recipients; each share is of general payments naming this product in 2025.
The top 5 of 6 specialties; each share is of general payments naming this product to practitioners with a specialty in 2025. Each practitioner is counted under their primary specialty.
The top 5 of 6 states; each share is of general payments naming this product in 2025 where a state was reported.
Records
72 general · 8 researchEvery payment, record by record
Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.
What you are looking at
Manufacturers name the drug, biological or device a payment relates to. CMS does not give products their own identifiers, so a product here is assembled from how it was reported — a brand may appear under more than one spelling, and this page covers one of them rather than the brand as a whole.